Loading...

Kancera

OTCPK:KNCQ.F
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KNCQ.F
OTCPK
SEK143M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The last earnings update was 65 days ago. More info.


Add to Portfolio Compare Print
KNCQ.F Share Price and Events
Price Volatility
KNCQ.F
Industry
5yr Volatility vs Market

Value

 Is Kancera undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Kancera. This is due to cash flow or dividend data being unavailable. The share price is $0.1137.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kancera's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kancera's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:KNCQ.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in SEK SEK-0.34
OM:KAN Share Price ** OM (2018-08-01) in SEK SEK0.75
United States of America Biotechs Industry PE Ratio Median Figure of 31 Publicly-Listed Biotechs Companies 24.54x
United States of America Market PE Ratio Median Figure of 2,953 Publicly-Listed Companies 18.09x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kancera.

OTCPK:KNCQ.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:KAN Share Price ÷ EPS (both in SEK)

= 0.75 ÷ -0.34

-2.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kancera is loss making, we can't compare its value to the US Biotechs industry average.
  • Kancera is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Kancera's expected growth come at a high price?
Raw Data
OTCPK:KNCQ.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.91x
United States of America Market PEG Ratio Median Figure of 2,071 Publicly-Listed Companies 1.21x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kancera, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kancera's assets?
Raw Data
OTCPK:KNCQ.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in SEK SEK0.30
OM:KAN Share Price * OM (2018-08-01) in SEK SEK0.75
United States of America Biotechs Industry PB Ratio Median Figure of 389 Publicly-Listed Biotechs Companies 3.22x
United States of America Market PB Ratio Median Figure of 4,958 Publicly-Listed Companies 1.83x
OTCPK:KNCQ.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:KAN Share Price ÷ Book Value per Share (both in SEK)

= 0.75 ÷ 0.30

2.52x

* Primary Listing of Kancera.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kancera is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Kancera's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Kancera has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Kancera expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kancera has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kancera expected to grow at an attractive rate?
  • Unable to compare Kancera's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Kancera's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Kancera's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:KNCQ.F Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.2%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 16.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:KNCQ.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:KNCQ.F Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2018-12-31 0 1
OTCPK:KNCQ.F Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-06-30 0 -41 -52
2018-03-31 1 -54 -59
2017-12-31 0 -54 -56
2017-09-30 0 -41 -51
2017-06-30 0 -40 -39
2017-03-31 0 -26 -27
2016-12-31 0 -23 -22
2016-09-30 0 -22 -22
2016-06-30 0 -19 -20
2016-03-31 0 -22 -20
2015-12-31 0 -21 -20
2015-09-30 0 -24 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Kancera is high growth as no earnings estimate data is available.
  • Unable to determine if Kancera is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:KNCQ.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Kancera Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KNCQ.F Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2018-12-31
OTCPK:KNCQ.F Past Financials Data
Date (Data in SEK Millions) EPS *
2018-06-30 -0.34
2018-03-31 -0.39
2017-12-31 -0.39
2017-09-30 -0.36
2017-06-30 -0.30
2017-03-31 -0.22
2016-12-31 -0.19
2016-09-30 -0.19
2016-06-30 -0.18
2016-03-31 -0.18
2015-12-31 -0.19
2015-09-30 -0.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kancera will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Kancera's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Kancera's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Kancera's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Kancera's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kancera has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Kancera performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kancera's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kancera does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Kancera's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Kancera's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Kancera's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kancera Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KNCQ.F Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 0.24 -51.64 4.94 46.75
2018-03-31 0.52 -59.01 4.90 54.62
2017-12-31 0.24 -56.20 5.38 51.07
2017-09-30 0.22 -50.59 5.28 45.62
2017-06-30 0.26 -39.45 4.07 35.53
2017-03-31 0.19 -26.94 3.94 23.12
2016-12-31 0.31 -22.31 3.44 19.09
2016-09-30 0.19 -21.74 5.42 21.60
2016-06-30 0.33 -19.80 5.12 20.20
2016-03-31 0.39 -19.73 4.87 20.44
2015-12-31 0.28 -19.61 4.75 20.36
2015-09-30 0.32 -18.79 2.91 16.18
2015-06-30 0.19 -18.38 2.97 15.60
2015-03-31 0.27 -16.72 2.56 14.39
2014-12-31 0.47 -15.98 2.57 13.69
2014-09-30 1.77 -13.03 2.66 11.71
2014-06-30 1.96 -12.76 3.27 10.87
2014-03-31 2.03 -12.28 4.12 9.51
2013-12-31 1.81 -7.42 4.15 7.53
2013-09-30 2.14 -16.05 4.61 14.71
2013-06-30 2.86 -19.74 4.68 18.62
2013-03-31 3.18 -25.00 2.85 25.71
2012-12-31 3.84 -33.49 5.38 28.88
2012-09-30 5.38 -27.78 4.74 24.21
2012-06-30 6.02 -26.58 4.60 22.99
2012-03-31 7.13 -26.95 5.49 23.10
2011-12-31 7.07 -18.41 3.77 23.04

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Kancera has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Kancera has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Kancera improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Kancera's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kancera has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Kancera's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kancera's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kancera is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kancera has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kancera's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Kancera has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kancera Company Filings, last reported 3 months ago.

OTCPK:KNCQ.F Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 56.20 0.00 52.70
2018-03-31 26.24 3.08 17.96
2017-12-31 38.71 2.95 27.78
2017-09-30 44.77 2.86 46.08
2017-06-30 60.09 2.89 54.10
2017-03-31 49.98 2.86 48.32
2016-12-31 59.53 2.86 57.76
2016-09-30 65.86 2.90 63.49
2016-06-30 71.10 0.00 68.69
2016-03-31 17.01 2.80 12.08
2015-12-31 21.93 1.50 15.57
2015-09-30 27.80 1.50 20.16
2015-06-30 31.16 1.50 25.35
2015-03-31 22.59 1.50 17.81
2014-12-31 27.29 1.50 22.97
2014-09-30 31.62 3.82 27.49
2014-06-30 33.84 3.32 31.09
2014-03-31 22.27 3.32 19.76
2013-12-31 18.96 1.50 14.12
2013-09-30 9.35 1.50 2.05
2013-06-30 12.09 1.50 3.97
2013-03-31 15.36 0.00 5.32
2012-12-31 5.50 6.92 6.84
2012-09-30 11.19 6.37 5.39
2012-06-30 17.62 6.55 13.25
2012-03-31 18.10 6.74 12.63
2011-12-31 25.90 7.61 20.84
  • Kancera has no debt.
  • Kancera has no debt compared to 5 years ago when it was 12.4%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Kancera has sufficient cash runway for 2.5 years based on current free cash flow.
  • Kancera has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 33.7% each year.
X
Financial health checks
We assess Kancera's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kancera has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Kancera's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kancera dividends.
If you bought $2,000 of Kancera shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kancera's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kancera's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:KNCQ.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 22 Stocks 2.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1976 Stocks 2.6%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:KNCQ.F Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kancera has not reported any payouts.
  • Unable to verify if Kancera's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kancera's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kancera has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Kancera's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kancera afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kancera has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Kancera's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Olin
COMPENSATION SEK2,980,000
AGE 60
CEO Bio

Mr. Thomas Olin, Ph.D. serves as the Chief Executive Officer of Kancera AB. Mr. Olin serves as Senior Director of Business Development at Biovitrum. He founded small biotech start-up. He has been Chief Executive Officer of iNovacia AB since 2006 and also serves as its Chairman. He served as Managing Director Biology, Director Business Development and Project Portfolio Manager of Biovitrum. He has 20 years of experience from Biotech and Big Pharma, mainly in Pharmacia and Biovitrum. He served as Project Portfolio Manager at Pharmacia and Managing Director of Biology and Director Business Development at Biovitrum. Mr. Olin serves as a Director of Kancera AB. He serves as a Director of iNovacia AB and Klaria Pharma Holding AB. He holds Ph.D. in physiology and M.Sc. in biology, chemistry and geosciences.

CEO Compensation
  • Thomas's compensation has increased whilst company is loss making.
  • Thomas's remuneration is about average for companies of similar size in United States of America.
Management Team

Thomas Olin

TITLE
CEO & Director
COMPENSATION
SEK3M
AGE
60

Martin Norin

TITLE
Chief Operating Officer
AGE
59

Joachim Forsgren

TITLE
Chief Medical Officer
AGE
64

Niclas Brynne

TITLE
Chief Development Officer
AGE
57

Johan Schultz

TITLE
Project Director of Preclinical
AGE
58
Board of Directors

Erik Nerpin

TITLE
Chairman of the Board
COMPENSATION
SEK150K
AGE
57

Thomas Olin

TITLE
CEO & Director
COMPENSATION
SEK3M
AGE
60

Håkan Mellstedt

TITLE
Director & Member of the Scientific Advisory Board
COMPENSATION
SEK116K
AGE
76

Carl-Henrik Heldin

TITLE
Director & Member of the Scientific Advisory Board
COMPENSATION
SEK100K
AGE
66

Charlotte Edenius

TITLE
Director & Member of the Scientific Advisory Board
COMPENSATION
SEK124K
AGE
60
TENURE
2.3 yrs

Anders Gabrielsen

TITLE
Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Max Price (SEK) Value (SEK)
08. May 18 Sell Håkan Mellstedt Individual 08. May 18 08. May 18 -643,440 SEK0.00 SEK-1,197.44
X
Management checks
We assess Kancera's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kancera has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. Its drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB inhibitors for reducing cancer’s energy supply and inhibiting DNA repair; HDAC6, an enzyme that controls the functions of the cell skeleton; and AZD8797 Fractalkine inhibitors that stop tumor growth and relieve severe pain. The company was founded in 2010 and is based in Solna, Sweden.

Details
Name: Kancera AB (Publ)
KNCQ.F
Exchange: OTCPK
Founded: 2010
SEK15,654,661
190,542,892
Website: http://www.kancera.com
Address: Kancera AB (Publ)
Karolinska Institutet Science Park,
Banvaktsvägen 22,
Solna,
Stockholm County, 171 48,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM KAN Common Shares OMX Nordic Exchange Stockholm SE SEK 28. Feb 2011
OTCPK KNCQ.F Common Shares Pink Sheets LLC US USD 28. Feb 2011
DB 3EE Common Shares Deutsche Boerse AG DE EUR 28. Feb 2011
Number of employees
Current staff
Staff numbers
0
Kancera employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/28 21:32
End of day share price update: 2018/08/01 00:00
Last estimates confirmation: 2018/10/11
Last earnings filing: 2018/08/24
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.